Donna Jo McCloskey

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Nurses' perceptions of research utilization in a corporate health care system
    Donna Jo McCloskey
    National Institutes of Health, National Center for Research Resources, Bethesda, MD, USA
    J Nurs Scholarsh 40:39-45. 2008
  2. ncbi Factor V Leiden as a common genetic risk factor for venous thromboembolism
    McDonald K Horne
    Department of Laboratory Medicine, National Institute of Nursing Research, National Institutes of Health, Bethesda 20892, USA
    J Nurs Scholarsh 38:19-25. 2006
  3. ncbi Selective serotonin reuptake inhibitors: measurement of effect on platelet function
    Donna Jo McCloskey
    National Institutes of Health, Warren Grant Magnuson Clinical Center, Department of Laboratory Medicine, Bethesda, MD 20892, USA
    Transl Res 151:168-72. 2008
  4. ncbi Parameters of coagulant and fibrinolytic capacity and activity in postmenopausal women: within-subject variability
    McDonald K Horne
    Department of Laboratory Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Thromb Res 107:229-33. 2002
  5. ncbi Catheter-related thrombosis in pediatrics
    Donna Jo McCloskey
    Department of Laboratory Medicine, Hematology Section, Warren Grant Magnussen Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Pediatr Nurs 28:97-102, 105-6. 2002
  6. ncbi Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices
    McDonald K Horne
    Department of Laboratory Medicine, W G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:1262-7. 2006

Detail Information

Publications6

  1. ncbi Nurses' perceptions of research utilization in a corporate health care system
    Donna Jo McCloskey
    National Institutes of Health, National Center for Research Resources, Bethesda, MD, USA
    J Nurs Scholarsh 40:39-45. 2008
    ....
  2. ncbi Factor V Leiden as a common genetic risk factor for venous thromboembolism
    McDonald K Horne
    Department of Laboratory Medicine, National Institute of Nursing Research, National Institutes of Health, Bethesda 20892, USA
    J Nurs Scholarsh 38:19-25. 2006
    ..Organizing Framework: An overview of the history, prevalence, and predisposition of the FVL genetic mutation, including who should be tested and how and in what circumstances people with FVL should be treated...
  3. ncbi Selective serotonin reuptake inhibitors: measurement of effect on platelet function
    Donna Jo McCloskey
    National Institutes of Health, Warren Grant Magnuson Clinical Center, Department of Laboratory Medicine, Bethesda, MD 20892, USA
    Transl Res 151:168-72. 2008
    ..Abnormal PFA-100 results suggest additional evaluation for von Willebrand disease, other platelet inhibitory medications, or underlying intrinsic platelet dysfunction...
  4. ncbi Parameters of coagulant and fibrinolytic capacity and activity in postmenopausal women: within-subject variability
    McDonald K Horne
    Department of Laboratory Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Thromb Res 107:229-33. 2002
    ..We observed large differences in within-subject variability among the tests and have demonstrated how such data can be used to estimate the number of times a parameter must be measured to produce a statistically adequate sample...
  5. ncbi Catheter-related thrombosis in pediatrics
    Donna Jo McCloskey
    Department of Laboratory Medicine, Hematology Section, Warren Grant Magnussen Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Pediatr Nurs 28:97-102, 105-6. 2002
    ..v.) therapy and blood sampling, but has decreased frequent trips to the clinics or hospitals that are otherwise often required. In recent years family members are using VADs more frequently at home for the delivery of medications...
  6. ncbi Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices
    McDonald K Horne
    Department of Laboratory Medicine, W G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:1262-7. 2006
    ..To determine whether lepirudin flushes are more effective than heparinized saline in preventing withdrawal occlusion of central venous access devices...